- Key facts & figures
- Sanofi share
- Analysts / Vara Consensus
- Reports & publications
- Results & presentations
- Corporate governance
Annual General Meetings
- Our publications
- Being a shareholder
- Becoming a shareholder
- Shareholders committee
- U.S. investors
- Regulated information in France
- Get to know Sanofi
- Working at Sanofi
- Our Expertise, your future
- Join Sanofi
- Being our partner
- Understanding science discovering
- Developing and marketing innovative solutions
- Manufacturing and supply
- Healthcare Solutions
- Our approach
- Improving access to healthcare
- Working together
- Ethics and transparency
- Preserving the environment
- ‘LE HUB’ eMAG
You are here:
Access to care for the underserved
Our objective is to improve access to healthcare and high-quality medications for underserved populations in our fields of expertise:
- Serving the needs of patients with non-communicable diseases
- Contributing to the eradication, elimination and control of some infectious diseases
To achieve this, we focus on 3 priorities :
- Delivering innovative medicines and vaccines to address unmet medical needs
- Development of new business/affordability models to improve access to healthcare
- Strengthening primary healthcare systems (capacity building, etc.)
As a global healthcare leader, Sanofi has a long-standing commitment to promote healthcare systems that make our treatments accessible and affordable.
Sanofi is one of many stakeholders in the healthcare system. However, we believe we have a role to play in order to maintain an ecosystem that will continue to bring new medicines and vaccines to patients.
The goal of our pricing principles is to increase the understanding of how we think about pricing, while also limiting our contribution to the increase in healthcare costs and offering more transparency into the overall process.
Through Sanofi Pasteur, our vaccines division, we envision a world in which no one suffers from a vaccine-preventable disease. We offer a wide range of vaccines against 20 diseases.
Learn more: Access to Vaccines - 2016 factsheet
Sanofi Pasteur launched the first vaccine against dengue, Dengvaxia®. As of December 2016, Dengvaxia® had been approved in 13 Asian and Latin American endemic countries.
In Malaysia, we have been collaborating with the Ministries of Health and Education since 2011 through our Dengue Patrol program. This program aims to educate schoolchildren about dengue and empower them to take action in dengue prevention activities. As of 2016, more than 250 primary and secondary schools (i.e. more than 12,500 students) were involved and 7,900 dengue patrollers had reached out to more than 200,000 people through preventive activities.
In 2016, Sanofi agreed to Principles of Collaboration with the Oswaldo Cruz Foundation (Fiocruz) and the Walter Reed Army Institute of Research (WRAIR) on the development of a potential Zika vaccine.
Through Sanofi Genzyme, we develop breakthrough therapies for patients who might otherwise have few treatment options. Sanofi Genzyme is committed to discovering and delivering transformative therapies to patients with rare and special unmet medical needs.
For more information:
September 20, 2017
August 21, 2017